Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Purchases 10,000 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were purchased at an average cost of $5.02 per share, for a total transaction of $50,200.00. Following the purchase, the chief executive officer now owns 2,285,731 shares in the company, valued at $11,474,369.62. This represents a 0.44 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Friday, February 28th, Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock. The stock was acquired at an average cost of $4.76 per share, with a total value of $47,600.00.
• On Tuesday, February 25th, Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock. The shares were acquired at an average cost of $4.46 per share, for a total transaction of $44,600.00.

Vanda Pharmaceuticals Trading Up 6.7 %

Shares of NASDAQ VNDA traded up $0.32 during midday trading on Wednesday, reaching $5.13. 1,253,506 shares of the company were exchanged, compared to its average volume of 672,243. The stock has a fifty day simple moving average of $4.59 and a 200 day simple moving average of $4.79. The stock has a market cap of $299.16 million, a P/E ratio of -16.03 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a 1 year low of $3.71 and a 1 year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06. The firm had revenue of $53.19 million during the quarter, compared to analysts’ expectations of $51.00 million. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. As a group, analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. Schonfeld Strategic Advisors LLC acquired a new stake in Vanda Pharmaceuticals during the fourth quarter worth approximately $1,296,000. Millennium Management LLC lifted its holdings in shares of Vanda Pharmaceuticals by 67.4% during the 4th quarter. Millennium Management LLC now owns 668,693 shares of the biopharmaceutical company’s stock worth $3,203,000 after acquiring an additional 269,183 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Vanda Pharmaceuticals in the fourth quarter worth approximately $1,221,000. Dimensional Fund Advisors LP grew its holdings in Vanda Pharmaceuticals by 10.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock valued at $11,920,000 after purchasing an additional 227,428 shares during the period. Finally, Monaco Asset Management SAM grew its holdings in Vanda Pharmaceuticals by 92.8% in the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company’s stock valued at $1,879,000 after purchasing an additional 188,836 shares during the period. 88.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on VNDA. StockNews.com began coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating on the stock. HC Wainwright upped their price objective on shares of Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.